GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (OTCPK:NOXOF) » Definitions » NonCurrent Deferred Liabilities

Noxopharm (Noxopharm) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Noxopharm NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Noxopharm's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.00 Mil.

Noxopharm NonCurrent Deferred Liabilities Historical Data

The historical data trend for Noxopharm's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm NonCurrent Deferred Liabilities Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial - - - - -

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Noxopharm NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Noxopharm's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Noxopharm (Noxopharm) Business Description

Industry
Traded in Other Exchanges
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.